Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084354 | 0.91 | BRD4 (0.36) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL2415069 | 0.91 | KDM4E (0.38) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL21120535 | 0.89 | HSD17B10 (0.38) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL17934305 | 0.88 | KDM4E (0.37) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL17928509 | 0.83 | CHRM1 (0.38) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL15064604 | 0.82 | BRD4 (0.38) | KDM4EALDH1A1HPGDTSHRRAB9A | |
| SCHEMBL16447915 | 0.81 | BRD4 (0.37) | KDM4EALDH1A1HPGDTSHRRAB9A | |
| SCHEMBL18567026 | 0.81 | HTT (0.35) | KDM4EALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL15913967 | 0.81 | RAB9A (0.39) | HSD17B10KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL15084306 | 0.80 | KDM4E (0.43) | HSD17B10KDM4EALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003435-A | Efficient green preparation method of dolutegravir | 河南师范大学 | 2023-04-25 | — | — | CN | claimed |
| CN-115746022-A | Preparation method and application of caspovir derivative | 河南科技大学 | 2023-03-07 | — | — | CN | claimed |
| EP-2549870-B1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2017-04-19 | — | — | EP | claimed |
| CN-116003435-A | Efficient green preparation method of dolutegravir | 河南师范大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-115746022-A | Preparation method and application of caspovir derivative | 河南科技大学 | 2023-03-07 | — | — | CN | disclosed |
| US-20170368040-A1 | Processes for Preparing Dolutegravir and Cabotegravir and Analogues Thereof | LEK PHARMACEUTICALS D.D. (SI) | 2017-12-28 | — | — | US | disclosed |
| EP-3260457-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3045461-A1 | Processes for preparing dolutegravir and analogues thereof | LEK Pharmaceuticals d.d. (SI) | 2016-07-20 | — | — | EP | disclosed |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | VIIV HEALTHCARE COMPANY | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368040-A1 | Processes for Preparing Dolutegravir and Cabotegravir and Analogues Thereof | SAMHD1, TYMP, DUT | HSD17B10 1658/4885KDM4E 1846/4885ALDH1A1 1922/4885 |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | CPS1, CYP3A4, DHPS | HSD17B10 1957/4885KDM4E 633/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.